<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208948</url>
  </required_header>
  <id_info>
    <org_study_id>DMP 77.1.99</org_study_id>
    <nct_id>NCT01208948</nct_id>
  </id_info>
  <brief_title>Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema</brief_title>
  <acronym>RETIPON</acronym>
  <official_title>Alpha Lipoic Acid in the Treatment of Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of alpha lipoic acid (ALA) on the occurrence of diabetic macular&#xD;
      edema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomised, double-blind, placebo controlled multicentre study. Patients were randomised to&#xD;
      the treatment group with 600 mg ALA per day or the placebo group. At each examination we took&#xD;
      stereo fundus photographs, HbA1c levels, and performed an ophthalmological examination.&#xD;
      Primary endpoint of the study was the occurrence of clinically significant macular edema&#xD;
      (CSME) within a follow-up period of 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of clinically significant macular edema (CSME) within a follow-up period of 2 years</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to CSME development</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">520</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Alpha lipoic acid 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1,2 dithiolane 3 valeric acid</intervention_name>
    <description>600 mg alpha lipoic acid per day</description>
    <arm_group_label>Alpha lipoic acid 600 mg</arm_group_label>
    <arm_group_label>placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetes type II, mild non proliferative diabetic retinopathy,&#xD;
&#xD;
          -  Microalbuminuria &gt; 30 mg/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ophthalmic exclusion criteria&#xD;
&#xD;
          -  severe non-proliferative or proliferative diabetic retinopathy&#xD;
&#xD;
          -  Macular edema&#xD;
&#xD;
          -  Eye diseases interfering with the examinations of the fundus such as preretinal&#xD;
             haemorrhage, cataract, vitreous haemorrhage&#xD;
&#xD;
          -  Amblyopia&#xD;
&#xD;
          -  Best corrected visual acuity (VA) over 0.5&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Patients with cataract surgery within a period of three months&#xD;
&#xD;
          -  Other relevant retinal diseases&#xD;
&#xD;
          -  Non-authorized interventional therapy of diabetic retinopathy (e.g. laser,&#xD;
             kryo-coagulation, vitrectomy)&#xD;
&#xD;
          -  General exclusion criteria&#xD;
&#xD;
          -  Chronic administration of alpha lipoic acid or of more than five successive days&#xD;
             during the last twelve months&#xD;
&#xD;
          -  Known intolerance/hypersensitivity to alpha lipoic acid&#xD;
&#xD;
          -  Type I diabetes mellitus&#xD;
&#xD;
          -  Poor metabolic control with HbA1c &gt;10.5 %/dl&#xD;
&#xD;
          -  Late sequelae of diabetes with organic manifestation (e.g. dialysis in cases of renal&#xD;
             insufficiency, history of kidney transplantation, creatinine &gt; 1.6 mg/dl)&#xD;
&#xD;
          -  Poorly controlled arterial hypertension (systolic blood pressure &gt; 160 mmHg and/or&#xD;
             diastolic blood pressure &gt; 95 mmHg)&#xD;
&#xD;
          -  Severe disturbances in lipid metabolism (triglycerides &gt; 500 mg/dl or total&#xD;
             cholesterol &gt; 320 mg/dl)&#xD;
&#xD;
          -  Unpermitted concomitant medication defined as any medicine with a potential&#xD;
             interaction with alpha lipoic acid or with the effect of alpha lipoic acid were&#xD;
             excluded as concomitant medication. These included aldose reductase inhibitors,&#xD;
             substances promoting blood flow, anticoagulants apart from acetylsalicylic acid 500&#xD;
             mg/day and short-term treatment of diseases with the normal dose of acetylsalicylic&#xD;
             acid, chronically and systemically administered corticosteroids, hormonal&#xD;
             contraceptives&#xD;
&#xD;
          -  Malignancies or life threatening diseases&#xD;
&#xD;
          -  Drug or alcohol abuse&#xD;
&#xD;
          -  Blood donation or blood loss greater than 500 ml) within the last 3 months&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Participation in a clinical trial within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Michael W Ulbig, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>September 23, 2010</last_update_submitted>
  <last_update_submitted_qc>September 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Anselm Kampik</name_title>
    <organization>Ludwig-Maximilians-University, Munich</organization>
  </responsible_party>
  <keyword>macular edema</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>prevention alpha lipoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

